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INTRODUCTION
Clinical data are present about close association of depressive disorders and pain. Interactions between pain perception and depressive symptoms in patients have been de-scribed. 1 Most of the patients with depression and pain do not respond to the pharmacological treatments. 2 The bilateral olfactory bulbectomy (OBX) syndrome in rats has been proposed as an animal model of depression. 3 OBX is associated with changes in behaviour, and in the endocrine, immune, and neurotransmitter systems, which simulate many of these seen in patients with major depression. 4 Recently, the endocannabinoid system has attracted much attention in relation to involvement in neuropsychiatric disorders such as major depression.
The endocannabinoid system is a biological system composed of endocannabinoids, cannabinoid receptors and the enzymes involved in the synthesis and inactivation of the neurotransmitters. 5, 6 Endocannabinoid signalling system has an important regulatory role throughout the nervous system that makes it potential therapeutic target for a wide range of disorders, including chronic pain, nausea, inflammation, cancer, cardiovascular disease, spasticity, epilepsy and immunomodulation. 7 The biological effects of cannabinoids are mediated via binding to type 1 (CB1) and type 2 (CB2) cannabinoid receptors which belong to the family of G-protein-coupled receptors. 5 The effects of cannabinoids in the central nervous system are mediated mainly by CB1 receptors. They are expressed at high density in different brain areas, where can be found mainly on the presynaptic nerve terminals. 8 Cannabinoid CB1 receptors are present also in brain regions involved in nociceptive perception, such as the thalamus, amygdala and brainstem. 9, 10 Numerous literature data provide evidence that cannabinoids produce antinociception by acting at peripheral, spinal, and supraspinal sites. 11 In the last few years, it has been found that the brain endocannabinoid system is involved in neuropsychiatric disorders such as major depression. There is increasing evidence that highlights the important role of the cannabinoid signalling in depression and nociception. 12, 13 The synthetic cannabinoid derivative HU 210 shows high potency to the CB1 receptors, whereas SR 141716A acts as a CB1 receptor antagonist.
AIM
The aim of the present study was to investigate the effect of CB1 receptor agonist HU 210 and CB1 receptor antagonist SR 141716A administered icv subchronically (for 7 days) on nociception of rats with experimental model of depression -bilateral olfactory bulbectomy.
MATERIALS AND METHODS
The experiments were carried out on 42 male Wistar rats (200-240 g at the time of surgery). The experiments were performed according to the Guide to the Care and Use of Experimental Animals of the Ethics Committee of the Institute of Neurobiology, Bulgarian Academy of Sciences.
Experimental model of depression -bilateral olfactory bulbectomy (OBX)
Bilateral olfactory bulbectomy was performed according to the method previously described. 3 The animals were anesthetized and placed in a stereotaxic apparatus (Stoelting, USA) and guide cannulae were implanted into ventriculus ventrolateralis dextra. One µl of drug solution HU 210 (5 µg) or SR 141716A (3 µg) were infused icv for 7 consecutive days, starting 15 days after the OBX procedure. On day 7, five minutes after the last microinjection, the rats were tested in an analgesy-meter.
Analgesy-meter test (paw-pressure)
The changes in the nociceptive response were determined by the foot-pressure method. A constantly increasing pressure was applied to the dorsal surface of the hind paw. The actual load applied was recorded in arbitrary units (AU) when the animal made its first escape attempt.
The animals were divided in two main clusters: cluster I consisting of group 1 -sham operated rats injected icv with saline; group 2 -sham operated rats + HU 210; group 3 -sham operated rat + SR141716A; cluster II consisting of group 1 -OBX+saline; group 2 -OBX+HU 210; and group 3 -OBX + SR141716.
Statistical analysis
Data were analysed by one-way ANOVA and further analysed by post hoc Student-Newman-Keuls (SNK) test.
RESULTS
Effects of HU 210 and SR 141716A infused icv in rats on nociception.
ANOVA demonstrated a significant effect for factor drug (F 2,20 = 23,7311; p ≤ 0.001) on pain threshold. HU 210 significantly increased (p ≤ 0.001) while the CB1 antagonist SR 141716A decreased the pain threshold (p ≤ 0.05) as compared to the saline treated sham operated controls ( Fig. 1) .
Effects of HU 210 and SR 141716A infused icv in OBX rats on nociception.
ANOVA showed a significance for factor bulbectomy (F 1,14 = 48,731; p ≤ 0.001). Post-hoc SNK test demonstrated that the olfactory bulbectomy increased the pain threshold (p ≤ 0.001) as compared to the sham operated controls. ANOVA demonstrated a significant effect for factor drug (F 2,20 = 18,8280; p ≤ 0.001).
HU-210, administered icv for 7 days in OBX rats decreased the pain threshold (p ≤ 0.001), while SR 141716A increased it (p ≤ 0.05) as compared to the saline treated OBX rats (Fig. 2) .
The comparison of the effects of the CB1 ligands in OBX rats to the effects exerted in the sham operated rats, revealed that HU 210 increased pain threshold (p ≤ 0.002), while SR 141716A produced a significant antinociceptive effect by increasing the pain threshold in comparison to both sham-operated rats (p ≤ 0.001) and HU 210 treated OBX rats (p ≤ 0.001) (Fig. 2) . 
DISCUSSION
The present study extended the understanding about the effects of cannabinoid ligands applied subchronically (7 days) icv on nociception of OBX rats. The CB1 receptors agonist HU-210 decreased pain sensitivity, i.e. exerted antinociceptive effect in the paw pressure test, while the CB1 receptor antagonist SR 141716A increased pain sensitivity to mechanical pressure i.e., produced hyperalgesia. Many animal models of depression support the clinical relationship between depression and pain. 14, 15 The clinical data have been confirmed in various experimental models of depression and pain. 15 Olfactory bulbectomy in rats is a widely used experimental model of depression which resembles major depression. 4 Removal of the olfactory bulbs leads to many behavioural, biochemical and cellular changes that are similar to the ones found in depressed patients. The lesion of the olfactory bulbs results in neurodegeneration in the different brain regions (cortex, amygdala and hippocampus) as the bulbs send projections to these areas. OBX syndrome is believed to result from dysfunction in brainstem and limbic areas accompanied by changes in many neurotransmitter systems. 3 Previously we have described an increased pain threshold of OBX rats, as compared to the sham operated controls, using Randall-Selitto analgesy-meter. Now we have found nociceptive effect of HU-210 by decreasing the pain threshold of OBX rats, while SR 141716A increased the pain threshold in OBX rats only compared to the shamoperated controls. As far as olfactory bulbectomy reduces the nociceptive response of rats in the analgesy-meter test, the effect of HU-210 could be interpreted as a tendency for an improvement of the nociceptive response. 16, 17 Previously we have found similar effects upon acute icv injection of HU-210 and SR 141716A. 17 Recently, it has been shown that cannabinoids play a role in nociceptive processes although the exact mechanisms by which they interfere in these processes are not well established. [18] [19] [20] [21] 
CONCLUSIONS
The results suggest an involvement of CB1 receptors in depression-like behaviour and nociception in OBX rats and support the evidence of the association between depressive disorder and pain pathways. The CB1 receptor ligands and especially the CB1 receptors agonists may be applied as potential antidepressant and analgesic agents although additional studies have to reveal their involvement in the mechanisms of depression and pain.
